Peregrine Reports Data Showing Bavituximab's Potential to Shrink Prost... (ody Improves Chemotherapyof Prostate Can...)

Peregrine Reports Data Showing Bavituximab's Potential to Shrink Prostate Tumors

Date:9/7/2007

ody Improves Chemotherapy of Prostate Cancer" by Yi Yin, Xianming Huang, Connie Chang, Steven W. King and Philip E. Thorpe will be presented at the Innovative Minds in Prostate Cancer Today (IMPaCT) Conference in Atlanta, Georgia on September 7, 2007 at 12:30 pm EDT. This conference is being hosted by the Department of Defense Prostate Cancer Research Program to showcase successes from the prostate cancer research being conducted with its funding.

This research was supported by the U.S. Army Medical Research and Materiel Command under W81XWH-06-1-0050 (DOD PC05031 grant) and a sponsored research agreement with Peregrine Pharmaceuticals, Inc.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that results of human studies will not correlate to the results achieved in connection with the preclinical results and the uncertainty as to whether the results of future clinical studies will support moving this product candidate forward for the treatment of prostate cancer. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; o
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
2. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
3. Peregrine Pharmaceuticals Highlights Significant Advances in the Companys Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting
4. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
5. Data Presented at AACR Meeting Show Peregrines Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer
6. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

Post Your Comments:

Peregrine Reports Data Showing Bavituximab's Potential to Shrink Prost...(ody Improves Chemotherapyof Prostate Can...),Health